Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
- Registration Number
- NCT01339559
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Brief Summary
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
- Detailed Description
The primary objective is to evaluate the long term safety and tolerability of BRV at individualized doses up to a maximum of 200 mg/day in epilepsy subjects.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 767
- Subject completed the Treatment Period of N01358 or the evaluation period of N01258
- Male/female subject from 16 years or older. Subject under 18 years may only be included where legally permitted and ethically accepted
- Subject for whom the Investigator believes a reasonable benefit from the long term administration of BRV may be expected
- Female subject without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible
- Subject has developed hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core studies
- Severe medical, neurological, or psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
- Poor compliance with the visit schedule or medication intake in the previous BRV study
- Planned participation in any other clinical study of another investigational drug or device during this study
- Pregnant or lactating woman
- Any medical condition which, in the Investigator's opinion, warrants exclusion
- Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Brivaracetam Brivaracetam Brivaracetam with a maximum of 200 mg/day
- Primary Outcome Measures
Name Time Method Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) From Entry Visit (Month 0) until the Last Visit (up to 84 months) Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.
Percentage of Participants Who Withdrew Due to Adverse Events (AEs) From Entry Visit (Month 0) until the Last Visit (up to 84 months) An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
Percentage of Participants With at Least One Serious Adverse Event (SAE) From Entry Visit (Month 0) until the Last Visit (up to 84 months) A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
* Results in death
* Is life-threatening
* Requires in patient hospitalization or prolongation of existing hospitalization
* Is a congenital anomaly or birth defect
* Is as infection that requires treatment parenteral antibiotics
* Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.
- Secondary Outcome Measures
Name Time Method Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period From Baseline of the previous study until the Last Visit (up to 84 months) The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as:
(the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.
Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.Responder Rate in POS (Type I) Frequency Over the Evaluation Period From Baseline of the previous study until the Last Visit (up to 84 months) A responder is defined as a subject with a โฅ 50% reduction in seizure frequency from the Baseline Period of the previous study.
Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period From Baseline of the previous study until the Last Visit (up to 84 months) The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.
Trial Locations
- Locations (184)
064
๐บ๐ธPort Charlotte, Florida, United States
011
๐บ๐ธDallas, Texas, United States
778
๐บ๐ธColumbus, Ohio, United States
070
๐บ๐ธColumbus, Ohio, United States
071
๐บ๐ธMiami, Florida, United States
701
๐ญ๐ฐHong Kong, Hong Kong
411
๐ญ๐บBudapest, Hungary
731
๐ฎ๐ณNashik, Maharashtra, India
126
๐ฒ๐ฝGuadalajara, Jalisco, Mexico
627
๐ฑ๐ปDaugavpils, Latvia
425
๐ฑ๐นAlytus, Lithuania
426
๐ฑ๐นVilnius, Lithuania
129
๐ฒ๐ฝAguascalientes, Mexico
412
๐ญ๐บBudapest, Hungary
726
๐ฎ๐ณBangalore, India
852
๐ฏ๐ตItami, Hyogo, Japan
403
๐ณ๐ฑZwolle, Netherlands
006
๐บ๐ธTucson, Arizona, United States
077
๐จ๐ฆGreenfield Park, Quebec, Canada
650
๐ช๐ชTallinn, Estonia
477
๐ต๐ฑPoznan, Poland
501
๐ท๐บKazan, Russian Federation
508
๐ท๐บSmolensk, Russian Federation
101
๐ง๐ทSao Paulo, Brazil
005
๐บ๐ธPeoria, Illinois, United States
009
๐บ๐ธGolden Valley, Minnesota, United States
042
๐บ๐ธHamilton, New Jersey, United States
017
๐บ๐ธWinfield, Illinois, United States
023
๐บ๐ธAtlanta, Georgia, United States
029
๐บ๐ธChicago, Illinois, United States
775
๐บ๐ธLittle Rock, Arkansas, United States
039
๐บ๐ธBoise, Idaho, United States
048
๐บ๐ธRome, Georgia, United States
022
๐บ๐ธNew York, New York, United States
078
๐จ๐ฆLondon, Ontario, Canada
294
๐ง๐ฌBlagoevgrad, Bulgaria
035
๐บ๐ธDallas, Texas, United States
076
๐จ๐ฆToronto, Ontario, Canada
301
๐ซ๐ทBethune, France
335
๐ฉ๐ชMuenchen, Germany
328
๐ฉ๐ชUlm, Germany
251
๐จ๐ฟOstrava, Czechia
902
๐ฉ๐ชErlangen, Germany
201
๐ฆ๐นLinz, Austria
275
๐ซ๐ฎKuopio, Finland
100
๐ง๐ทFlorianopolis, Brazil
777
๐บ๐ธDallas, Texas, United States
916
๐จ๐ฟKromeriz, Czechia
331
๐ฉ๐ชGรถttingen, Germany
015
๐บ๐ธPhiladelphia, Pennsylvania, United States
286
๐ง๐ฌSofia, Bulgaria
652
๐ช๐ชTallinn, Estonia
651
๐ช๐ชTartu, Estonia
384
๐ฎ๐นReggio Calabria, Italy
079
๐จ๐ฆMontreal, Canada
104
๐ง๐ทBelo Horizonte, Brazil
256
๐จ๐ฟOstrava, Czechia
054
๐บ๐ธTulsa, Oklahoma, United States
252
๐จ๐ฟPraha 1, Czechia
327
๐ฉ๐ชKiel, Germany
380
๐ฎ๐นFirenze, Italy
376
๐ฎ๐นPerugia, Italy
227
๐ง๐ชLeuven, Belgium
287
๐ง๐ฌSofia, Bulgaria
332
๐ฉ๐ชBielefeld, Germany
334
๐ฉ๐ชOsnabruck, Germany
917
๐จ๐ฟBrno, Czechia
253
๐จ๐ฟPraha 4, Czechia
250
๐จ๐ฟZlin, Czechia
377
๐ฎ๐นMonserrato, Italy
386
๐ฎ๐นNapoli, Italy
750
๐ฐ๐ทSeoul, Korea, Republic of
528
๐ช๐ธBarcelona, Spain
330
๐ฉ๐ชRavensburg, Germany
900
๐ฉ๐ชMarburg, Germany
379
๐ฎ๐นMilano, Italy
729
๐ฎ๐ณMadurai, India
375
๐ฎ๐นPisa, Italy
607
๐ฌ๐งNewcastle, United Kingdom
753
๐ฐ๐ทBusan, Korea, Republic of
526
๐ช๐ธValladolid, Spain
725
๐ฎ๐ณMumbai, India
130
๐ฒ๐ฝMexico City, Mexico
378
๐ฎ๐นBari, Italy
751
๐ฐ๐ทSeoul, Korea, Republic of
754
๐ฐ๐ทSeoul, Korea, Republic of
854
๐ฏ๐ตYokohama-City, Japan
125
๐ฒ๐ฝDistrito Federal, Mexico
629
๐ฑ๐ปJekabpils, Latvia
628
๐ฑ๐ปRiga, Latvia
485
๐ต๐ฑGdansk, Poland
793
๐ต๐ฑKrakow, Poland
483
๐ต๐ฑLublin, Poland
795
๐ต๐ฑKatowice, Poland
540
๐ช๐ธBarcelona, Spain
503
๐ท๐บMoscow, Russian Federation
529
๐ช๐ธBarcelona, Spain
535
๐ช๐ธBarcelona, Spain
800
๐จ๐ณTainan, Taiwan
600
๐ฌ๐งLondon, United Kingdom
551
๐ธ๐ชGoteborg, Sweden
552
๐ธ๐ชLinkoping, Sweden
539
๐ช๐ธSan Sebastian, Spain
532
๐ช๐ธSantiago de Compostela, Spain
602
๐ฌ๐งMorriston, Swansea, United Kingdom
806
๐จ๐ณKaohsiung City, Taiwan
537
๐ช๐ธValencia, Spain
801
๐จ๐ณTaichung, Taiwan
803
๐จ๐ณTaoyuan, Taiwan
601
๐ฌ๐งTruro, United Kingdom
605
๐ฌ๐งMiddlesborough, United Kingdom
034
๐บ๐ธCleveland, Ohio, United States
020
๐บ๐ธAmes, Iowa, United States
098
๐บ๐ธPoughkeepsie, New York, United States
069
๐บ๐ธIowa City, Iowa, United States
002
๐บ๐ธToledo, Ohio, United States
049
๐บ๐ธHouston, Texas, United States
043
๐บ๐ธOklahoma City, Oklahoma, United States
001
๐บ๐ธPhoenix, Arizona, United States
008
๐บ๐ธBethesda, Maryland, United States
013
๐บ๐ธPhoenix, Arizona, United States
060
๐บ๐ธAurora, Colorado, United States
025
๐บ๐ธSan Francisco, California, United States
776
๐บ๐ธNashville, Tennessee, United States
003
๐บ๐ธDurham, North Carolina, United States
091
๐บ๐ธOklahoma City, Oklahoma, United States
057
๐บ๐ธMilwaukee, Wisconsin, United States
036
๐บ๐ธCharlottesville, Virginia, United States
068
๐บ๐ธWaldorf, Maryland, United States
032
๐บ๐ธLebanon, New Hampshire, United States
099
๐บ๐ธNew York, New York, United States
010
๐บ๐ธAsheville, North Carolina, United States
050
๐บ๐ธMansfield, Texas, United States
913
๐จ๐ฟOstrava Poruba, Czechia
329
๐ฉ๐ชBerlin, Germany
305
๐ซ๐ทMontpellier, France
326
๐ฉ๐ชBernau, Germany
727
๐ฎ๐ณHyderabad, India
855
๐ฏ๐ตHiroshima, Japan
383
๐ฎ๐นPozzilli, Italy
127
๐ฒ๐ฝCuliacan, Mexico
128
๐ฒ๐ฝGuadalajara, Jalisco, Mexico
400
๐ณ๐ฑHeeze, Netherlands
475
๐ต๐ฑBialystok, Poland
038
๐ต๐ทSan Juan, Puerto Rico
480
๐ต๐ฑKatowice, Poland
476
๐ต๐ฑKrakow, Poland
481
๐ต๐ฑKatowice, Poland
791
๐ต๐ฑGdansk, Poland
478
๐ต๐ฑKatowice, Poland
794
๐ต๐ฑWarszawa, Poland
527
๐ช๐ธValencia, Spain
550
๐ธ๐ชStockholm, Sweden
603
๐ฌ๐งBirmingham, United Kingdom
608
๐ฌ๐งSalford, United Kingdom
276
๐ซ๐ฎTampere, Finland
202
๐ฆ๐นInnsbruck, Austria
851
๐ฏ๐ตShizuoka, Japan
625
๐ฑ๐ปValmiera, Latvia
427
๐ฑ๐นKaunas, Lithuania
027
๐บ๐ธOrlando, Florida, United States
075
๐จ๐ฆCalgary, Alberta, Canada
226
๐ง๐ชHechtel-Eksel, Belgium
413
๐ญ๐บSzekszard, Hungary
728
๐ฎ๐ณMumbai, India
203
๐ฆ๐นWien, Austria
414
๐ญ๐บHajdรบ-Bihar, Hungary
850
๐ฏ๐ตOsaka, Japan
479
๐ต๐ฑPoznan, Poland
509
๐ท๐บNizhny Novgorod, Russian Federation
021
๐บ๐ธPort Royal, South Carolina, United States
028
๐บ๐ธCharleston, South Carolina, United States
080
๐จ๐ฆSaskatoon, Saskatchewan, Canada
410
๐ญ๐บBudapest, Hungary
502
๐ท๐บMoscow, Russian Federation
401
๐ณ๐ฑHeemstede, Netherlands
482
๐ต๐ฑPoznan, Poland
488
๐ต๐ฑWarszawa, Poland
506
๐ท๐บKazan, Russian Federation
061
๐บ๐ธAustin, Texas, United States
780
๐บ๐ธLexington, Kentucky, United States
052
๐บ๐ธMadison, Wisconsin, United States
056
๐บ๐ธSpokane, Washington, United States
700
๐ญ๐ฐHong Kong, Hong Kong